| |
Newsroom /
Health and Fitness
/
Healthcare
/
HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
HIV-AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
HIV/AIDS Therapeutics Market is Forecast to Grow Until 2017
Hyderabad,
AP,
India
(prbd.net)
12/05/2011
GlobalData estimated the HIV/AIDS therapeutics market to be worth $12.3 billion in 2010. GlobalData expects the HIV/AIDS therapeutics market to grow at a compound annual growth rate (CAGR) of 5% from $12.3 billion in 2010 to approximately $17.3 billion in 2017. The introduction of multi-class combination products has contributed to the growth of the market.
GlobalData found that the currently available products in the market are highly efficacious in providing protection against the disease with only minimum side-effects. Key products such as Atripla (efavirenz tenofovir emtricitabine), Truvada (tenofovir emtricitabine), Sustiva (efavirenz), Kaletra (lopinavir/ritonavir), Reyataz (Atazanavir Sulfate) and Isentress (raltegravir) are able to satisfy the demand in the HIV/AIDS
market.
The HIV/AIDS therapeutics market has high unmet need as the market is not well served by the current product options. Subsequently, there is scope for new entrants to capitalize on the market. The HIV market consists of a large number of drugs that are approved for HIV, however, none can cure the disease.
The new products have to aim at achieving market share by providing unique offerings that will target the untapped market. The likely untapped segment is the availability of single-tablet regimens that are effective, safe and well tolerated. Moreover there is a need for new disease modifying therapies that will stop disease progression.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=HIV-AIDS-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry
GlobalData analysis shows that the HIV/AIDS therapeutic pipeline is strong, with approximately 147 molecules in various phases of clinical development, including 108 first-in-class molecules. These first-inclass molecules have distinct advantages over the current market products in terms of overall survival rates and improved efficacy and safety profiles, which mean they could satisfy the market’s unmet need in these areas. If approved, these products will stimulate intense competition in the market and the existing
market leaders will need to respond quickly in the race to develop a blockbuster drug with higher efficacy and safety profiles.
GlobalData has released its new report, “HIV/AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global HIV/AIDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=HIV-AIDS-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|